Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.09T
24h Vol:
$8.59B
Dominance:
MSFT:4.90%
Stocklytics Platform
Asset logo for symbol CERT
Certara
CERT
54
$14.89arrow_drop_up1.70%$0.25

Performance History

Chart placeholder
Key Stats
Open$14.50
Prev. Close$14.64
EPS-0.39
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$2.65B
PE Ratio-
LOWHIGH
Day Range14.38
14.94
52 Week Range11.81
19.87
Ratios
P/B Ratio2.70
Revenue$354.33M
Operating M. %-1.33%
Earnings$0.00
Earnings Growth %-475.79%
EBITDA Margin %25.33%
ROE %-5.74%
EPS-0.39

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

info
There's no data available for Analyst Forecast

Analyst Ratings

info
There's no data available for Analyst Ratings

Correlated Companies

PRICE$878.45
24H (%)arrow_drop_down0.55%
24H ($)-$4.88
MARKET CAP$771.28B
PRICE$497.12
24H (%)arrow_drop_down0.03%
24H ($)-$0.17
MARKET CAP$443.63B
PRICE$145.53
24H (%)arrow_drop_up0.06%
24H ($)$0.09
MARKET CAP$347.62B
PRICE$129.48
24H (%)arrow_drop_up0.08%
24H ($)$0.11
MARKET CAP$318.88B

About Certara (CERT)

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, the Netherlands, the Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Sector
Healthcare
Industry
Health Information Services
CEO
Dr. William F. Feehery Ph.D.
Headquarters
Princeton
Employees
1150
Exchange
NASDAQ
add Certara to watchlist

Keep an eye on Certara

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Certara's (CERT) price per share?

The current price per share for Certara (CERT) is $14.89. The stock has seen a price change of $0.25 recently, indicating a 1.71% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Certara (CERT)?

For Certara (CERT), the 52-week high is $19.87, which is 33.45% from the current price. The 52-week low is $11.81, the current price is 26.08% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Certara (CERT) a growth stock?

Certara (CERT) has shown an average price growth of 0.41% over the past three years. It has received a score of 29 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Certara as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Certara (CERT) stock price performance year to date (YTD)?

As of the latest data, Certara (CERT) has a year-to-date price change of -14.18%. Over the past month, the stock has experienced a price change of -6.47%. Over the last three months, the change has been -19.34%. Over the past six months, the figure is -12.41%.

help
Is Certara (CERT) a profitable company?

Certara (CERT) has a net income of -$55.36M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 47.35% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.33% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $354.34M, with a revenue growth rate of 5.57%, providing insight into the company's sales performance and growth. The gross profit is $167.79M. Operating income is noted at $14.06M. Furthermore, the EBITDA is $66.1M.

help
What is the market capitalization of Certara (CERT)?

Certara (CERT) has a market capitalization of $2.65B. The average daily trading volume is 676.29K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level